GYROSCOPE THERAPEUTICS LIMITED
Get an alert when GYROSCOPE THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-05-03 (in 1y)
Last made up 2026-04-19
Watchouts
Cash
—
Latest balance sheet
Net assets
£25M
+116.7% vs 2023
Employees
32
-68% vs 2023
Profit before tax
£262K
+100.2% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
Therefore, the financial statements have been prepared on a non-going concern basis which the directors consider to be appropriate for the above-mentioned reasons. No specific accounting policies were affected by this decision.
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£111,542,000 | £7,198,000 | |
| Profit before tax | -£116,527,000 | £262,000 | |
| Net profit | -£95,550,000 | -£14,540,000 | |
| Cash | — | — | |
| Total assets less current liabilities | -£150,325,000 | £25,135,000 | |
| Net assets | -£150,325,000 | £25,135,000 | |
| Equity | -£150,325,000 | £25,135,000 | |
| Average employees | 100 | 32 | |
| Wages | £12,475,000 | £3,301,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | 74.2% | 28.6% | |
| Interest cover | -23.32x | 0.99x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“Therefore, the financial statements have been prepared on a non-going concern basis which the directors consider to be appropriate for the above-mentioned reasons. No specific accounting policies were affected by this decision.”
Significant events
- “On September 6, 2023, Novartis AG announced the discontinuation of the PPY988 (GT005) development program in geographic atrophy (GA), including wind down of active studies. (Page 4)”
- “During 2024, the Company completed the sale of its IP for GBP 18.1m, resulting in a net gain of GBP 13m. (Page 4)”
- “A GBP 33.1m payable to Gyroscope Therapeutics Holding Ltd. was formally waived during 2024; income recognised within other operating income. (Page 4)”
- “On 14 December 2024, board decided to transfer business (except office lease) to Novartis Pharmaceuticals UK Limited; agreement signed 17 June 2025. (Page 5, 28)”
- “During 2024, research and development expenses reduced to £9.6m (2023: £28.4m) due to discontinuation of programs (FYH474 - GT011 and CYE472-GT013) earlier in 2023. (Page 4)”
- “The Company received a capital contribution of GBP 190m from its parent undertaking, Novartis Pharma AG, recognised directly in equity. (Page 14)”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 27 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CULLEN, Richard Samuel | Secretary | 2026-01-01 | — | — |
| BHATT, Chinmay Umesh | Director | 2023-11-14 | Oct 1973 | Dutch |
| GUPTA, Sandeep | Director | 2025-05-12 | Jun 1982 | Indian |
| KAHLSTROEM, Johan Mikael Olof | Director | 2024-11-01 | Jul 1980 | Swedish |
Show 27 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CULLEN, Richard Samuel | Secretary | 2022-02-17 | 2022-07-20 |
| JOHNSTON, Elaine | Secretary | 2021-10-04 | 2022-02-17 |
| ROBINSON, Timothy William | Secretary | 2022-07-20 | 2026-01-01 |
| OLSWANG COSEC LIMITED | Corporate Secretary | 2016-04-18 | 2021-10-04 |
| BEKKALI, Soraya, Dr | Director | 2017-07-12 | 2019-07-31 |
| BHATT, Chinmay Umesh | Director | 2022-02-17 | 2022-05-31 |
| BOHEN, Sean | Director | 2020-09-07 | 2021-10-01 |
| BROOKS, Jason Mark | Director | 2022-02-17 | 2025-04-08 |
| CLARK, Ian Thornton | Director | 2019-03-26 | 2021-10-15 |
| CLARK, Ian Thornton | Director | 2019-03-26 | 2019-08-30 |
| COOK, Jennifer Elizabeth | Director | 2020-11-01 | 2021-09-30 |
| FAROOQ, Khurem | Director | 2019-03-26 | 2021-10-04 |
| FELLOWS, David | Director | 2020-12-01 | 2021-10-01 |
| GALA, Renee | Director | 2020-11-01 | 2021-10-10 |
| GAMACHE, Marie-Andree Renee | Director | 2022-06-29 | 2024-10-31 |
| GROENDAHL, Christian, Dr | Director | 2016-04-18 | 2016-04-18 |
| HOLLOWOOD, Dr Christopher, Dr | Director | 2016-04-18 | 2021-09-29 |
| HOPKINS, Janet Jill, Dr | Director | 2022-02-17 | 2023-10-13 |
| JOUSTRA, Wouter Sebastiaan Johannes | Director | 2021-03-29 | 2021-10-08 |
| KATABI, Maha, Dr | Director | 2021-03-29 | 2021-10-10 |
| KAVANAGH, David | Director | 2016-05-12 | 2019-02-04 |
| MCANALLY, Gerard David, Dr | Director | 2021-10-04 | 2022-02-17 |
| PRENER, Anne | Director | 2017-07-12 | 2019-04-01 |
| PROSSER, Andrew Michael James | Director | 2021-10-04 | 2022-02-17 |
| SCHMIDT, Dominic, Dr | Director | 2019-02-14 | 2021-03-29 |
| THOMAS, Iain Paul, Dr | Director | 2017-07-12 | 2019-08-30 |
| WALSH, Andy Peter | Director | 2016-05-12 | 2017-07-11 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Gyroscope Therapeutics Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-04-15 | Active |
| Syncona Limited | Corporate entity | Shares 75–100%, Voting 75–100% | 2017-03-24 | Ceased 2021-04-15 |
Filing timeline
Last 20 of 182 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-05 | AP03 | officers | Appoint person secretary company with name date | |
| 2026-01-05 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-09-10 | AA | accounts | Accounts with accounts type full | |
| 2025-05-13 | AP01 | officers | Appoint person director company with name date | |
| 2025-04-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-04-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-01-14 | CH01 | officers | Change person director company with change date | |
| 2024-11-05 | AP01 | officers | Appoint person director company with name date | |
| 2024-11-04 | TM01 | officers | Termination director company with name termination date | |
| 2024-10-14 | AA | accounts | Accounts with accounts type full | |
| 2024-09-17 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2024-04-23 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-11-16 | AP01 | officers | Appoint person director company with name date | |
| 2023-11-14 | AA | accounts | Accounts with accounts type full | |
| 2023-10-17 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-01 | CH01 | officers | Change person director company with change date | |
| 2023-08-04 | AD03 | address | Move registers to sail company with new address | |
| 2023-08-04 | AD02 | address | Change sail address company with new address | |
| 2023-05-02 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
+116.7%
-£150,325,000 £25,135,000
-
Employees
-68%
100 32
-
Operating profit
+106.5%
-£111,542,000 £7,198,000
-
Profit before tax
+100.2%
-£116,527,000 £262,000
-
Wages
-73.5%
£12,475,000 £3,301,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers